Bank of New York Mellon’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-10,930
| Closed | -$3K | – | 4610 |
|
|
2022
Q3 | $3K | Hold |
10,930
| – | – | ﹤0.01% | 4546 |
|
|
2022
Q2 | $4K | Hold |
10,930
| – | – | ﹤0.01% | 4577 |
|
|
2022
Q1 | $7K | Hold |
10,930
| – | – | ﹤0.01% | 4651 |
|
|
2021
Q4 | $25K | Hold |
10,930
| – | – | ﹤0.01% | 4575 |
|
|
2021
Q3 | $50K | Hold |
10,930
| – | – | ﹤0.01% | 4438 |
|
|
2021
Q2 | $49K | Sell |
10,930
-43,068
| -80% | -$219K | ﹤0.01% | 4329 |
|
|
2021
Q1 | $394K | Sell |
53,998
-1,829
| -3% | -$15K | ﹤0.01% | 3813 |
|
|
2020
Q4 | $427K | Buy |
55,827
+26,633
| +91% | +$178K | ﹤0.01% | 3693 |
|
|
2020
Q3 | $265K | Buy |
29,194
+239
| +0.8% | +$1.81K | ﹤0.01% | 3765 |
|
|
2020
Q2 | $245K | Buy |
28,955
+8,103
| +39% | +$53.3K | ﹤0.01% | 3746 |
|
|
2020
Q1 | $103K | Hold |
20,852
| – | – | ﹤0.01% | 3854 |
|
|
2019
Q4 | $151K | Hold |
20,852
| – | – | ﹤0.01% | 3966 |
|
|
2019
Q3 | $225K | Sell |
20,852
-1,887
| -8% | -$20.2K | ﹤0.01% | 3877 |
|
|
2019
Q2 | $295K | Sell |
22,739
-222
| -1% | -$2.95K | ﹤0.01% | 3813 |
|
|
2019
Q1 | $227K | Buy |
+22,961
| New | +$214K | ﹤0.01% | 3845 |
|
Bank of New York Mellon's LOGC Position: Q4 2022 in Review
Bank of New York Mellon sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 10,930 shares — an estimated $3K sold.
Bank of New York Mellon first reported a position in LOGC in Q1 2019 and held it in 15 quarters. The position peaked at $427K in Q4 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Bank of New York Mellon reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Bank of New York Mellon sold 10,930 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $3K.
- Bank of New York Mellon first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
- Bank of New York Mellon's LogicBio Therapeutics, Inc. Common Stock position peaked at $427K in Q4 2020.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.